↓ Skip to main content

Government Patent Use to Address the Rising Cost of Naloxone: 28 U.S.C. § 1498 and Evzio

Overview of attention for article published in Journal of Law, Medicine & Ethics, January 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#40 of 957)
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
3 news outlets
policy
1 policy source
twitter
10 tweeters

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
18 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Government Patent Use to Address the Rising Cost of Naloxone: 28 U.S.C. § 1498 and Evzio
Published in
Journal of Law, Medicine & Ethics, January 2021
DOI 10.1177/1073110518782954
Pubmed ID
Authors

Alex Wang, Aaron S. Kesselheim

Abstract

The rising cost of the opioid antagonist and overdose reversal agent naloxone is an urgent public health problem. The recent and dramatic price increase of Evzio, a naloxone auto-injector produced by Kaléo, shows how pharmaceutical manufacturers entering the naloxone marketplace rely on market exclusivity guaranteed by the patent system to charge prices at what the market can bear, which can restrict access to life-saving medication. We argue that 28 U.S.C. § 1498, a section of the federal code that allows the government to use patent-protected products for its own purposes in exchange for reasonable compensation, could be used to procure generic naloxone auto-injectors, or at least bring Kaléo to the negotiating table. Precedent exists for the use of § 1498 to procure pharmaceuticals, and it could give meaning to the federal government's recent declaration of a public health emergency around the opioid epidemic, discourage new market entrants from charging exorbitant prices, and yield important public health benefits.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 22%
Student > Bachelor 3 17%
Student > Master 3 17%
Professor 1 6%
Other 1 6%
Other 1 6%
Unknown 5 28%
Readers by discipline Count As %
Economics, Econometrics and Finance 2 11%
Nursing and Health Professions 2 11%
Medicine and Dentistry 2 11%
Social Sciences 2 11%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Other 3 17%
Unknown 6 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2020.
All research outputs
#677,539
of 16,479,843 outputs
Outputs from Journal of Law, Medicine & Ethics
#40
of 957 outputs
Outputs of similar age
#20,337
of 279,332 outputs
Outputs of similar age from Journal of Law, Medicine & Ethics
#1
of 33 outputs
Altmetric has tracked 16,479,843 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 957 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,332 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.